Sunday, January 20, 2019
In-transit melanoma metastases and PV-10 vs isolated limb perfusion, an update...
I have been writing about intralesional/intratumoral treatments for melanoma for a LOOOOONG time! My first post was about PV-10 in 2012!!! If you're interested for a walk back in time and the initial thoughts, here you go: Rose Bengal sustains high response rate in Melanoma patients!!! Here are a zillion posts/articles regarding intralesional treatments since, with the last being in December of 2018: Intralesional therapy for melanoma ~ from TVEK, PV-10, CAVATAK, to SD101 and beyond!
I have also been keeping an eye on its use for those with in-transit melanoma as well. Here are posts specific to that: In-transit Melanoma
And for the purposes of comparison, relative to the article at hand, here are some posts on isolated limb perfusion:
From 2014: In-Transit Melanoma..a little info
From 2018: Chemo via isolated limb perfusion followed by ipi = response rate of 85% in 26 melanoma patients
Now there is this updated by Read, et al:
Patients with in-transit melanoma metastases have comparable survival outcomes following isolated limb infusion or intralesional PV-10-A propensity score matched, single center study. Read, Fayers, Thomas, et al. J Surg Oncol. 2019 Jan 15.
While ain't nuthin a done deal in melanoma land, I am glad that intralesionals are proving helpful to more melanoma patients and melanoma researchers are working toward finding the best ways to utilize it on its own and in combination with systemic therapies for the greatest benefit. I hope that more intralsional options, in addition to TVEC, will be FDA approved soon. I long for head to head comparisons. Still - it is progress and that is good. Thanks, ratties. - c